Online Database of Chemicals from Around the World Search | Submit | Advertising

chemBlink >> Chemical Listing >> ARQ 197>> Market Analysis Reports
 




Market Analysis Reports of ARQ 197

CAS 1000873-98-2 ARQ 197 Chemical Report & Database
CAS 1000873-98-2 ARQ 197 Chemical Report & Database This ARQ 197 Chemical World ... The ARQ 197 World Consumption Report & Database definitions: Name: ARQ 197: ARQ-197; (3R,4R)-3-(5,6- ... Chemical or Reaction Intermediate The ARQ 197 Report & Database gives Market ...

ArQule Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
... Stage Products ARQ 197: c-Met Inhibitor The company’s primary product is ARQ 197, a non- ... agreement focuses on the co-development of ARQ 197 to treat cancer. The agreement ... Inc. In addition, with respect to ARQ 197, the company is aware of various companies ...

ArQule Inc (ARQL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
... . Its lead product candidate, ARQ 197 (tivantinib), an inhibitor of the c-Met ... is a multi-kinase inhibitor, ARQ 092 is an Akt inhibitor, ARQ 751 is a next-generation ... inhibitor of Akt, ARQ 761 is an activator ...

KYOWA HAKKO KIRIN - ARQ-197 Enters Japanese Ph III - Success Will Boost KHK’s Onco Ambitions!
... to initiate Ph III JP trial for ARQ-197 (Ph II, c-Met inhibitor, advance or metastatic ... survival (OS) of patients treated with ARQ 197 and Tarceva (erlotinib) vs. placebo ... suggest favorable outcome in Ph III. ARQ-197, if reaches market, will be targeting ~ 3 ...

CAS 905854-02-6 Tivantinib Chemical Report & Database
... definitions: Name: Tivantinib: Tivantinib; ARQ 197; (3R,4R)-3-(5,6-Dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol ... -3-yl)pyrrolidine-2,5-dione Synonyms: ARQ 197; (3R,4R)-3-(5,6-Dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl) ...

Covid-19 Impact on Global RAC Beta Serine/Threonine Protein Kinase Industry Research Report 2020 Segmented by Major Market Players, Types, Applications and Countries Forecast to 2026
The research team projects that the RAC Beta Serine/Threonine Protein Kinase market size will grow from XXX in 2019 to XXX by 2026, at an estimated CAGR of XX. The base year considered for the study is 2019, and the market size is projected from 2020 to ...

Covid-19 Impact on Global Sickle Cell Disease Drug Industry Research Report 2020 Segmented by Major Market Players, Types, Applications and Countries Forecast to 2026
The research team projects that the Sickle Cell Disease Drug market size will grow from XXX in 2019 to XXX by 2026, at an estimated CAGR of XX. The base year considered for the study is 2019, and the market size is projected from 2020 to 2026. The prime ...

Liver Cancer Drugs: Market Research Report
This report analyzes the Global market for Liver Cancer Drugs in US$ Million. Annual estimates and forecasts are provided for the period 2007 through 2015. The report profiles 40 companies including 4SC AG, Actavis Group, Inc., Alnylam Pharmaceuticals, Inc ...

Apoptosis: Market Research Report
This report analyzes the worldwide markets for Apoptosis in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Europe, Asia Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the ...

Non-small cell lung cancer: Game changing immunotherapies to revolutionise treatment - KOL Insight
Change is coming to the NSCLC treatment algorithm—and it’s coming soon. Revolutionary new immunotherapies, more personalised treatment choices and further drug developments are all set to roll out in the near future. What are the potential blockbusters, ...

ARQULE - Read-Out Only in 2013
We remain positive on potential of Tivantinib (formerly ARQ-197, PhIII, c-MET inhibitor, 2nd/3rd- ... ) but cautious on the B-RAF program, ARQ-736 (PhI, pan-Raf inhibitor ...

ARQULE - Positive Data in HCC is an Add-On!
Positive PhII data of Tivantinib (formerly ARQ-197, c-MET inhibitor) in 2nd line HepatoCellular ...








Copyright ©  chemBlink. All rights reserved. Content Disclaimer | About chemBlink | Contact